We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Sarepta Therapeutics (SRPT) Stock Soared on Tuesday
Read MoreHide Full Article
Shares of Sarepta Therapeutics (SRPT - Free Report) closed 8.4% higher on Tuesday, and were up as much as 12% in earlier in the trading session after it announced positive data for its Duchenne Muscular Dystrophy (DMD) drug.
SRP-9001 is an investigational gene transfer therapy intended to deliver a micro-dystrophin-encoding gene to muscle tissue. DMD causes muscle degeneration and weakness and alters thedystrophin protein that helps keep muscle cells intact.
20 participants between the ages of 4 and 7 were treated in the study. All showed robust transduction, with average dystrophin level of 55.4% of normal. Overall, SRP-9001 demonstrated “[a] consistent safety profile.” Mizuho Securities analyst Difei Yang told clients in a note that these positive results are an important step for Sarepta to begin Phase 3 testing.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Why Sarepta Therapeutics (SRPT) Stock Soared on Tuesday
Shares of Sarepta Therapeutics (SRPT - Free Report) closed 8.4% higher on Tuesday, and were up as much as 12% in earlier in the trading session after it announced positive data for its Duchenne Muscular Dystrophy (DMD) drug.
SRP-9001 is an investigational gene transfer therapy intended to deliver a micro-dystrophin-encoding gene to muscle tissue. DMD causes muscle degeneration and weakness and alters thedystrophin protein that helps keep muscle cells intact.
20 participants between the ages of 4 and 7 were treated in the study. All showed robust transduction, with average dystrophin level of 55.4% of normal. Overall, SRP-9001 demonstrated “[a] consistent safety profile.” Mizuho Securities analyst Difei Yang told clients in a note that these positive results are an important step for Sarepta to begin Phase 3 testing.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>